Iressa Oral Tablet 250Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Iressa: Oral tablet (250mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_971.JPG
Iressa 250mg Tab
AstraZeneca Pharmaceuticals LP
Pill Identification: IRESSA 250 

What is this Medicine?

GEFITINIB (ge FI ti nib) is a chemotherapy drug. It targets a specific enzyme within cancer cells and stops the cancer cells from growing. It is used to treat advanced non-small cell lung cancer. To receive this medicine, you will be enrolled in the Iressa Access Program. The medicine will be provided by a special mail-order pharmacy.

In-Depth Information

Iressa 250mg Tablet

NDC: 003100482
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Non-small Cell Lung Cancer (NSCLC)

Sometimes used for but not FDA approved for the following conditions:
Head And Neck Cancer

Storage Information
Store at controlled room temperature (between 68 and 77 degrees F)
Iressa 250mg Tablet
Drug Image file DrugItem_971.JPG
AstraZeneca Pharmaceuticals LP
Pill Identification: IRESSA 250 
Shape: round
Color: brown

Reported Side Effects for Iressa 250mg Tablet

Eye Inflammatoin Incidence:
0.1%*
Severity: SEVERE
Onset: DELAYED
Inflamed Pancreas Incidence:
0.1%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
0.5%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
0.7%*
Severity: SEVERE
Onset: DELAYED
Lung Inflammation Incidence:
0.7%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
1.2%*
Severity: SEVERE
Onset: EARLY
Dehydration Incidence:
1.8%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
2.0%*
Severity: MODERATE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
2.0-5.1%*
Severity: SEVERE
Onset: DELAYED
Dry Mouth Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
2.3%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Bleeding Incidence:
4.3%*
Severity: MODERATE
Onset: EARLY
Hair Loss Incidence:
4.7%*
Severity: MILD
Onset: DELAYED
Protein In The Urine Incidence:
4.7%*
Severity: SEVERE
Onset: DELAYED
Dry Eyes Incidence:
6.7%*
Severity: MILD
Onset: EARLY
Fever Incidence:
9.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Iressa 250mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Grapefruit juice and Iressa 250mg Tablet(Gefitinib)
Grapefruit juice and Gefitinib(Gefitinib)
Do not take Gefitinib and Grapefruit Juice together without talking to your health care provider. Side effects from Gefitinib may get worse if you take Grapefruit Juice or grapefruit-containing foods. Notify your health care provider if you notice increased eye irritation and/or pain, shortness of breath or difficulty breathing, nausea, vomiting, sores in mouth, or other unusual effects.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Iressa

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5